|
Market Closed -
Euronext Paris
19:55:00 30/10/2026 +03
|
5-day change | 1st Jan Change | ||
| 0.0953 EUR | -1.24% |
|
-0.83% | -99.89% |
| 06-30 | Neovacs bolsters its strategic intellectual property portfolio |  |
| 04-30 | Neovacs S.A. Auditor Raises 'Going Concern' Doubt | CI |
"Total Return" performance includes dividend payments over the period, as if they were reinvested at 100%.
The annotated values (TR) are displayed with their "Total Return" performance (only if available).
End-of-day quotes
The annotated values (TR) are displayed with their "Total Return" performance (only if available).
End-of-day quotes
Sector Other Biotechnology & Medical Research
| Capi. | Sales Growth | Profitability | Finances | EV / Sales | P/E | |
|---|---|---|---|---|---|---|
 | 16.92K | - | - | - | - | - |
| 63.77B | |||||
| 56.37B | |||||
| 54.62B | |||||
| 44.06B | |||||
| 42.11B |
- Stock Market
- Stocks
- ALNEV Stock
- Charts NEOVACS
- Sector Chart
Select your edition
All financial news and data tailored to specific country editions
